Actinium Pharmaceuticals (NYSE American: ATNM), a company developing targeted alpha radiotherapies, is advancing its solid-tumor program with a Phase 1 clinical trial in South Africa targeting B7-H3. This study represents one of the earliest clinical explorations of the company’s ATNM-400 platform, which uses the alpha-emitting isotope Actinium-225 (Ac-225) to deliver highly potent radiation directly to cancer cells.

The South African trial marks a meaningful development step at a time when interest in radiopharmaceuticals is accelerating globally. As oncology researchers and investors look for treatment options capable of overcoming resistance in late-stage cancers, alpha-based radiotherapy programs like ATNM-400 have entered the spotlight.

Growing Interest in Radiopharmaceuticals

The radiopharmaceutical sector has experienced a surge of attention due to several industry-shaping trends:

• Strong M&A activity from major pharmaceutical companies

• Advances in isotope availability, especially Ac-225

• Successful early-stage results across targeted radiation approaches

• Demand for next-generation treatments that can work even when tumors stop responding to established therapies

These dynamics have created a favorable landscape for companies like Actinium that possess both platform depth and long-term experience with high-energy radioisotopes.

ATNM-400: A Targeted Alpha Radiotherapy Platform

ATNM-400 is designed to pair tumor-targeting molecules with the highly potent Ac-225 isotope. Although each target within the platform is explored independently, Actinium recently shared preclinical findings demonstrating strong anti-tumor activity for ATNM-400 across multiple major solid tumors, including:

• Prostate cancer

• EGFR-mutant non-small cell lung cancer (NSCLC)

• Breast cancers, including hormone-resistant and HER2-resistant disease

These findings support the overall platform architecture behind the B7-H3 program, suggesting ATNM-400 may have multi-tumor potential depending on the target selected.

Why B7-H3 Is an Important Target

B7-H3 has been studied widely across oncology because of its presence in several solid tumor types and its limited expression in normal tissue. While Actinium has not released B7-H3-specific efficacy data, the target’s prevalence makes it a compelling candidate for alpha-based radiotherapy exploration.

The South Africa Phase 1 trial is designed to evaluate:

• Safety and tolerability

• Biodistribution and tumor targeting

• Early signs of biological effect

• Suitability for advancing into broader development

The region’s nuclear medicine infrastructure and experienced clinical centers make it a logical choice for this early-phase evaluation.

Why South Africa Matters

South Africa has been expanding its capabilities in oncology research and radiopharmaceutical development. Factors making it an attractive clinical region include:

• Established nuclear medicine centers

• Strong radiodiagnostic and radiotherapy infrastructure

• Growing interest in precision oncology research

• Diverse patient populations supporting early-stage feasibility work

For Actinium, conducting a Phase 1 trial in South Africa demonstrates international expansion at a time when global radiopharma development is becoming more common.

How This Program Fits Into Actinium’s Broader Strategy

Although the B7-H3 program is its own dedicated clinical effort, Actinium is exploring multiple targets within the ATNM-400 family. These include:

• STEAP-1 (associated with prostate, breast, and lung cancers)

• Nectin-4 (evaluated in a Phase 1 trial in Europe)

• Trop-2 (in Phase 1/2 trials in the U.S. and Australia)

These additional programs provide Actinium with multiple potential pathways for development as ATNM-400 matures.

Investor Perspective

The B7-H3 South Africa trial contributes to several key themes investors are tracking:

• Rapid growth of the radiopharmaceutical sector

• Increasing recognition of alpha therapy potential

• Multi-target platform flexibility

• Global expansion into international clinical sites

• New preclinical ATNM-400 data demonstrating multi-tumor applicability

By anchoring one of its early clinical efforts in South Africa, Actinium is building a diversified development foundation and positioning itself among the radiopharmaceutical companies advancing next-generation treatment strategies for solid tumors.

Disclaimers: RazorPitch Inc. “RazorPitch” is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by Awareness Consulting to assist in the production and distribution of content related to ANTM. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content.

Media Contact
Company Name: RazorPitch
Contact Person: Mark McKelvie
Email: Send Email
City: NAPLES
State: Florida
Country: United States
Website: https://razorpitch.com/